CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 138 enrolled
Drug / intervention
PF-06647020 Q3W +3 moredrug
Likely dose
PF-06647020 Q3W 0.20mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02222922
NCT02222922Phase 1Completed
CompareCT.gov

A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647020 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

Pfizer·interventional·Posted Aug 22, 2014·Updated Dec 17, 2020

In Brief

A Phase 1 clinical trial evaluating PF-06647020 Q3W, fluconazole, and 2 other interventions for Neoplasms. Completed, enrolled 138 participants across 17 sites in 2 countries.

Detailed Summary

To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesSpain, United States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 22, 2014
Enrollment StartOct 17, 2014
Primary CompletionNov 5, 2019
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 11.9 years ago

Interventions

PF-06647020 Q3Wdrug

Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined. Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.

fluconazoledrug

combination drug used for drug-drug interaction sub-study

PF-06647020 Q2Wdrug

Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined. Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.

PF-06647020 combined with Avelumabdrug

Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.